New and experimental hepatitis C treatment

New and experimental hepatitis C treatment features

• 

  Full speed ahead to curing hepatitis C

  New drugs that directly target the hepatitis C virus usher in a new era of treatment, Liz Highleyman reports. ...

  From:  HIV treatment update

• 

  We’re getting there: towards a comprehensive hepatitis C cure

  Research on new cures for hepatitis C has made rapid progress, Gus Cairns reports....

  From:  HIV treatment update

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:  HIV treatment update

New and experimental hepatitis C treatment news from aidsmap

• Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients

  A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had factors predictive of poor response, researchers reported last week at the 20th Conference on Retroviruses and Opportunistic Infections ...

  20 March 2013 | Liz Highleyman

• AbbVie interferon-free combinations cure most newly treated hepatitis C patients

  All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis  C patients – including those with unfavourable IL28B gene patterns – but ...

  20 March 2013 | Liz Highleyman

• Adding telaprevir improves acute hepatitis C treatment for HIV-positive men

  Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented last ...

  12 March 2013 | Liz Highleyman

• Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

  An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the phase 2a COSMOS trial, according to a presentation last ...

  12 March 2013 | Liz Highleyman

• Faldaprevir ups interferon response in HIV/HCV co-infection

  Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential for shorter treatment for HIV/HCV co-infected people, according to a presentation last ...

  11 March 2013 | Liz Highleyman

• Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection

  Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with a shortened course of therapy, researchers reported last week at the ...

  11 March 2013 | Liz Highleyman

• French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

  Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.The advent of ...

  05 March 2013 | Liz Highleyman

• Sofosbuvir/ledipasvir/ribavirin cures 100% of genotype 1 hepatitis C patients

  An interferon-free regimen containing sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders, according to data presented yesterday at the ...

  05 March 2013 | Liz Highleyman

• Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients?

  An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was well-tolerated and produced four-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot study, researchers reported at The Liver ...

  12 December 2012 | Liz Highleyman

• Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

  Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported at The Liver Meeting 2012, the ...

  05 December 2012 | Liz Highleyman

More news

New and experimental hepatitis C treatment news selected from other sources

• Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim

  The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.

  13 March 2013 | Presidio press release

• Pfizer stops developing hepatitis C drug

  Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

  10 March 2013 | EATG

• Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

  Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate.

  07 March 2013 | AIDSMeds

• UNITAID can address HCV/HIV co-infection

  In the first days of March, the governing body of UNITAID, the organisation financed mainly through a levy on air tickets, will decide on a new 4-year strategy. We believe UNITAID's new strategy should also include tackling a prevalent and serious, but curable, HIV co-morbidity: hepatitis C virus (HCV) infection.

  23 February 2013 | The Lancet

• Regulators Await Gilead's Hep C Candidate

  Gilead Sciences’ (GILD) sofosbuvir has passed all its preliminary examinations, and now is looking like a good bet for regulatory submissions in the coming months.

  22 February 2013 | Seeking Alpha

• Study may help design better DAA drug cocktails to treat HCV

  The new study documents HCV kinetic modeling during treatment both in patients and in cell culture that provides insight into the modes of action of daclatasvir. In addition, the study suggests a more accurate estimate of HCV clearance from circulation.

  20 February 2013 | News Medical

• Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

  Initial Regulatory Filings Planned for Q2 2013. Gilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior treatment.

  19 February 2013 | Gilead press release

• HCV polymerase inhibitor mericitabine boosts interferon/ribavirin cure rate

  A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.

  13 February 2013 | HIVandHepatitis.com

• FISSION Study Should Support Regulatory Approval For Gilead's Hepatitis C Drug

  On Monday, Gilead announced positive top‐line results from two Phase III studies (FISSION and NEUTRINO) that involve the use of sofosbuvir in combination with other agents for use in treatment‐naïve patients infected with the Hepatitis C virus (HCV).

  07 February 2013 | Seeking Alpha

• Idenix to Discontinue Development of Two Hepatitis C Treatments

  Idenix Pharmaceuticals today announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.

  05 February 2013 | Idenix press release

More news